2018
Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008–2011
Wilson LE, Pollack CE, Greiner MA, Dinan MA. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008–2011. Breast Cancer Research And Treatment 2018, 170: 361-371. PMID: 29536319, DOI: 10.1007/s10549-018-4746-6.Peer-Reviewed Original ResearchConceptsMedical oncologistsPhysician characteristicsBreast cancerGenomic testingMedicare beneficiariesAmerican Medical Association Physician Master FileNode-negative breast cancerEarly-stage breast cancerReceipt of testingMethodsRetrospective cohort studyYear of diagnosisPhysician-level factorsPhysician-level characteristicsMultivariable regression modelsAdjuvant chemotherapyCohort studyRS testingOptimal careResultsA totalStudy criteriaSurgical oncologySurgical proceduresHigher oddsMAIN OUTCOMELower odds
2015
Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009
Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncology 2015, 1: 158-166. PMID: 26181015, DOI: 10.1001/jamaoncol.2015.43.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGuideline AdherenceHealthcare DisparitiesHumansMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypePractice Guidelines as TopicPractice Patterns, Physicians'Predictive Value of TestsRacial GroupsResidence CharacteristicsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsIntermediate-risk diseaseBreast cancerRecurrence scoreClinical practiceNode-negative breast cancerNational Comprehensive Cancer NetworkAdjuvant chemotherapy useIncident breast cancerComprehensive Cancer NetworkEnd Results (SEER) dataHigh-grade diseaseRetrospective observational studyRoutine clinical practiceTumor histologic characteristicsMedicare coverage decisionsAdjuvant chemotherapyChemotherapy useN1 diseaseMost patientsComorbid conditionsMultivariable analysisRS assayClinical variablesStudy criteriaBlack race